<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dose modification for molecularly targeted agents used for cancer therapy in patients with preexisting liver disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dose modification for molecularly targeted agents used for cancer therapy in patients with preexisting liver disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dose modification for molecularly targeted agents used for cancer therapy in patients with preexisting liver disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Liver function</td> <td class="subtitle1">Percent dose reduction administered initially*</td> </tr> <tr> <td>Acalabrutinib</td> <td>Severe hepatic impairment</td> <td>Avoid use</td> </tr> <tr class="highlight_gray_text"> <td>Alectinib</td> <td>Severe hepatic impairment</td> <td>Reduce initial starting dose</td> </tr> <tr> <td>Axitinib</td> <td>Refer to UpToDate text</td> <td> </td> </tr> <tr class="highlight_gray_text"> <td>Binimetinib</td> <td>Moderate or severe hepatic impairment</td> <td>Reduce initial starting dose from 45 to 30 mg orally twice daily</td> </tr> <tr> <td>Bosutinib</td> <td> </td> <td>Reduced starting doses (200 mg daily) for mild, moderate, or severe hepatic impairment</td> </tr> <tr class="highlight_gray_text"> <td>Brentuximab</td> <td> </td> <td>Reduce starting dose for mild liver impairment; avoid use for moderate to severe hepatic impairment</td> </tr> <tr> <td>Brigatinib</td> <td>Severe hepatic impairment</td> <td>Reduce initial starting dose</td> </tr> <tr class="highlight_gray_text"> <td>Ceritinib</td> <td>Severe hepatic impairment</td> <td>Reduce initial starting dose</td> </tr> <tr> <td>Crizotinib</td> <td>Moderate to severe hepatic impairment (total serum bilirubin or AST &gt;1.5 times the ULN)</td> <td>Reduce initial starting dose</td> </tr> <tr class="highlight_gray_text"> <td>Enfortumab</td> <td>Moderate or severe hepatic impairment</td> <td>Avoid use</td> </tr> <tr> <td>Erlotinib</td> <td>Direct bilirubin 1 to 7 mg/dL or ALT ≥3 times the ULN</td> <td>Start at 75 rather than 150 mg daily</td> </tr> <tr class="highlight_gray_text"> <td rowspan="3">Everolimus</td> <td>Child-Pugh A</td> <td>25% dose reduction for patients treated for breast cancer, renal cell cancer, or pancreatic neuroendocrine tumor; for patients with subependymal giant cell tumor, refer to manufacturer's FDA-approved package insert</td> </tr> <tr class="highlight_gray_text"> <td>Child-Pugh B</td> <td>50% reduction for patients treated for breast cancer, renal cell cancer, or pancreatic neuroendocrine tumor; for patients with subependymal giant cell tumor, refer to manufacturer's FDA-approved package insert</td> </tr> <tr class="highlight_gray_text"> <td>Child-Pugh C</td> <td>If potential benefits outweigh risks, maximum daily dose of 2.5 mg recommended</td> </tr> <tr> <td rowspan="2">Ibrutinib</td> <td>Child-Pugh A</td> <td>140 rather than 420 mg daily</td> </tr> <tr> <td>Child-Pugh B or C</td> <td>Avoid use</td> </tr> <tr class="highlight_gray_text"> <td>Imatinib</td> <td>Total bilirubin &gt;3 to 10 times the ULN</td> <td>25% dose reduction<sup>¶</sup></td> </tr> <tr> <td>Infigratinib</td> <td>Mild or moderate hepatic impairment</td> <td>Reduce initial starting dose</td> </tr> <tr class="highlight_gray_text"> <td>Lapatinib</td> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>1250 mg per day initial dose (in conjunction with capecitabine) reduced to 750 mg once daily; 1500 mg per day initial dose (in conjunction with letrozole) reduced to 1000 mg once daily</td> </tr> <tr> <td>Larotrectinib</td> <td>Moderate or severe hepatic impairment</td> <td>Reduce starting dose by 50%</td> </tr> <tr class="highlight_gray_text"> <td>Lenvatinib</td> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>Reduce initial dose from 24 to 12 mg once daily</td> </tr> <tr> <td>Neratinib</td> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>Reduce starting dose from 240 to 80 mg daily</td> </tr> <tr class="highlight_gray_text"> <td rowspan="2">Nilotinib</td> <td>Mild to moderate impairment (Child-Pugh A/B)</td> <td>600 rather than 800 mg daily</td> </tr> <tr class="highlight_gray_text"> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>400 mg daily</td> </tr> <tr> <td>Pazopanib</td> <td>Total bilirubin ≥1.5 times the ULN and/or ALT ≥2 times the ULN</td> <td>Reduce to 200 mg daily</td> </tr> <tr class="highlight_gray_text"> <td>Pemigatinib</td> <td>Severe hepatic impairment (total bilirubin &gt;3 times the ULN)</td> <td>Reduce initial starting dose</td> </tr> <tr> <td>Ponatinib</td> <td>Moderate to severe hepatic impairment (Child-Pugh B/C)</td> <td>Avoid use</td> </tr> <tr class="highlight_gray_text"> <td>Regorafenib</td> <td>Child-Pugh C disease</td> <td>Avoid use</td> </tr> <tr> <td>Ribociclib</td> <td>Moderate to severe hepatic impairment (Child-Pugh B/C)</td> <td>Reduce starting dose from 600 to 400 mg daily</td> </tr> <tr class="highlight_gray_text"> <td>Ruxolitinib</td> <td>Refer to UpToDate text</td> <td>Recommendations for dose modification vary according to indications for use.</td> </tr> <tr> <td>Selpercatinib</td> <td>Total bilirubin &gt;3 to 10 times the ULN, and any AST elevation</td> <td>Reduce initial dose to 80 mg orally twice daily</td> </tr> <tr class="highlight_gray_text"> <td>Sunitinib</td> <td>Refer to UpToDate text</td> <td> </td> </tr> <tr> <td rowspan="2">Temsirolimus</td> <td>Total bilirubin &gt;1 to 1.5 times the ULN or AST greater than the ULN</td> <td>Reduce dose to 15 mg per week</td> </tr> <tr> <td>Total bilirubin &gt;1.5 times the ULN</td> <td>Avoid use</td> </tr> <tr class="highlight_gray_text"> <td>Tucatinib</td> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>Reduced initial dose</td> </tr> <tr> <td>Zanubrutinib</td> <td>Severe hepatic impairment (Child-Pugh C)</td> <td>Reduced initial dose</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>AST: aspartate aminotransferase; ULN: upper limit of normal; ALT: alanine aminotransferase; FDA: US Food and Drug Administration.</p>
<p>* Subsequent doses may be escalated as tolerated.</p>
¶ Others<sup>[1]</sup> suggest the need to limit the total daily dose to 500 mg even in the setting of mild liver impairment (bilirubin &lt;1.5 times the ULN).</div><div class="graphic_reference">Reference:
<ol>
<li>Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.</li>
</ol></div><div id="graphicVersion">Graphic 81280 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
